Germany · Delayed Price · Currency is EUR Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of EUR 147.31 billion. The enterprise value is 158.44 billion.
| Market Cap | 147.31B |
| Enterprise Value | 158.44B |
Important Dates
The next estimated earnings date is Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | Mar 13, 2026 |
Share Statistics
| Current Share Class | 1.24B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 89.20% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 20.32 and the forward PE ratio is 15.74.
| PE Ratio | 20.32 |
| Forward PE | 15.74 |
| PS Ratio | 5.87 |
| PB Ratio | 7.65 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.29 |
| P/OCF Ratio | 17.26 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.42, with an EV/FCF ratio of 19.67.
| EV / Earnings | 21.86 |
| EV / Sales | 6.22 |
| EV / EBITDA | 12.42 |
| EV / EBIT | 15.50 |
| EV / FCF | 19.67 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.55 |
| Quick Ratio | 1.23 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 1.73 |
| Debt / FCF | 2.70 |
| Interest Coverage | 11.54 |
Financial Efficiency
Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.
| Return on Equity (ROE) | 40.66% |
| Return on Assets (ROA) | 12.52% |
| Return on Invested Capital (ROIC) | 26.86% |
| Return on Capital Employed (ROCE) | 25.03% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | 1.48M |
| Profits Per Employee | 426,351 |
| Employee Count | 17,000 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 3.58 |
Taxes
In the past 12 months, Gilead Sciences has paid 1.10 billion in taxes.
| Income Tax | 1.10B |
| Effective Tax Rate | 13.13% |
Stock Price Statistics
The stock price has increased by +21.22% in the last 52 weeks. The beta is 0.37, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +21.22% |
| 50-Day Moving Average | 121.65 |
| 200-Day Moving Average | 105.55 |
| Relative Strength Index (RSI) | 36.56 |
| Average Volume (20 Days) | 879 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.63 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of EUR 25.08 billion and earned 7.25 billion in profits. Earnings per share was 5.77.
| Revenue | 25.08B |
| Gross Profit | 19.77B |
| Operating Income | 10.06B |
| Pretax Income | 8.34B |
| Net Income | 7.25B |
| EBITDA | 12.42B |
| EBIT | 10.06B |
| Earnings Per Share (EPS) | 5.77 |
Balance Sheet
The company has 8.19 billion in cash and 21.75 billion in debt, with a net cash position of -11.03 billion.
| Cash & Cash Equivalents | 8.19B |
| Total Debt | 21.75B |
| Net Cash | -11.03B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 19.26B |
| Book Value Per Share | 15.58 |
| Working Capital | 5.56B |
Cash Flow
In the last 12 months, operating cash flow was 8.53 billion and capital expenditures -479.51 million, giving a free cash flow of 8.05 billion.
| Operating Cash Flow | 8.53B |
| Capital Expenditures | -479.51M |
| Depreciation & Amortization | 2.39B |
| Net Borrowing | -1.55B |
| Free Cash Flow | 8.05B |
| FCF Per Share | n/a |
Margins
Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.
| Gross Margin | 78.84% |
| Operating Margin | 40.14% |
| Pretax Margin | 33.27% |
| Profit Margin | 28.90% |
| EBITDA Margin | 49.51% |
| EBIT Margin | 40.14% |
| FCF Margin | 32.12% |
Dividends & Yields
This stock pays an annual dividend of 2.74, which amounts to a dividend yield of 2.30%.
| Dividend Per Share | 2.74 |
| Dividend Yield | 2.30% |
| Dividend Growth (YoY) | -4.64% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 47.04% |
| Buyback Yield | 0.24% |
| Shareholder Yield | 2.54% |
| Earnings Yield | 4.92% |
| FCF Yield | 5.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 7 |